- Home
- SCKT vs KZIA Comparison
SCKT vs KZIA Comparison
Compare SCKT & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCKT
- KZIA
- Stock Information
- Founded
- SCKT 1992
- KZIA 1994
- Country
- SCKT United States
- KZIA Australia
- Employees
- SCKT N/A
- KZIA N/A
- Industry
- SCKT Computer Manufacturing
- KZIA Biotechnology: Pharmaceutical Preparations
- Sector
- SCKT Technology
- KZIA Health Care
- Exchange
- SCKT Nasdaq
- KZIA Nasdaq
- Market Cap
- SCKT 9.8M
- KZIA 9.0M
- IPO Year
- SCKT 1995
- KZIA 1999
- Fundamental
- Price
- SCKT $1.02
- KZIA $8.00
- Analyst Decision
- SCKT
- KZIA Strong Buy
- Analyst Count
- SCKT 0
- KZIA 2
- Target Price
- SCKT N/A
- KZIA $14.00
- AVG Volume (30 Days)
- SCKT 12.0K
- KZIA 137.3K
- Earning Date
- SCKT 10-23-2025
- KZIA 06-05-2025
- Dividend Yield
- SCKT N/A
- KZIA N/A
- EPS Growth
- SCKT N/A
- KZIA N/A
- EPS
- SCKT N/A
- KZIA N/A
- Revenue
- SCKT $16,710,984.00
- KZIA $1,549,158.00
- Revenue This Year
- SCKT $8.62
- KZIA N/A
- Revenue Next Year
- SCKT N/A
- KZIA $49.25
- P/E Ratio
- SCKT N/A
- KZIA N/A
- Revenue Growth
- SCKT N/A
- KZIA 248983.08
- 52 Week Low
- SCKT $0.85
- KZIA $2.86
- 52 Week High
- SCKT $1.72
- KZIA $39.05
- Technical
- Relative Strength Index (RSI)
- SCKT 43.22
- KZIA 49.43
- Support Level
- SCKT $1.01
- KZIA $7.60
- Resistance Level
- SCKT $1.09
- KZIA $8.88
- Average True Range (ATR)
- SCKT 0.04
- KZIA 0.59
- MACD
- SCKT 0.00
- KZIA 0.06
- Stochastic Oscillator
- SCKT 15.00
- KZIA 48.57
About SCKT Socket Mobile Inc.
Socket Mobile Inc is a producer of data capture products. The company's products are integrated into mobile applications used in mobile point of sale (mPOS), commercial services (field workers), asset tracking, manufacturing process and quality control, transportation and logistics (goods tracking and movement), event management (ticketing, entry, access control, and identification), medical and education. The company offers barcode scanning products for both one-dimensional, including imager and laser, and two-dimensional barcode scanning in standard and durable cases. The company's geographical segments are the Americas, Europe, Asia Pacific, and Africa, of which the majority of the revenue is generated from the United States.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is an oncology-focused biotechnology company, developing anti-cancer drugs. The group is developing paxalisib, a potential treatment for glioblastoma; Cantrixil, being developed for the treatment of ovarian cancer; and Others. The company is also developing EVT801 for the treatment of various tumors. Maximum of revenue is earned from South Korea.